Systems Biology in Pharmacogenomic Research: The Way to Personalized Prescribing?

Abstract

Response to pharmacotherapy can be highly variable amongst individuals. Pharmacogenomics may explain the interindividual variability in drug response due to genetic variation. However, besides genetics, many other factors can play a role in the response to pharmacotherapy, including disease severity, co-morbidity, environmental factors, therapy adherence and co-medication use. Better understanding of these factors and inter-relationships should bring about a much more effective approach to disease management. Systems biology that studies organisms as integrated and interacting networks of genes, proteins and biochemical reactions can contribute to this. Organisms are no longer studied part by part, but in a more integral manner. Integration of the genetic data with intermediate and end point phenotypic characterization may prove essential to define the inherent nature of drug effects. Therefore, in the future, a multidisciplinary systems-based approach will be necessary to deal with the bulk of the biological data that is available and, ultimately, to reach the goal of personalized prescribing.

KEYWORDS::

• data integration
• drug response
• pathways
• pathways
• systems biology

Financial & competing interest disclosure

Ellen S Koster received an unrestricted grant from GlaxoSmithKline. Anke-Hilse Maitland-van der Zee is funded by a Veni grant from the Netherlands Organization for Scientific Research (NWO). Andrei S Rodin is funded by the grants from PhRMA foundation, NIH, Gilson-Longenbaugh foundation and UTHSC Office of Biotechnology Seed Grant Program. He holds (minor) stock in Pfizer. Jan AM Raaijmakers is a part-time professor at the Utrecht University and vice president external scientific collaborations for GlaxoSmithKline in Europe and holds stock in GlaxoSmithKline. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

Ellen S Koster received an unrestricted grant from GlaxoSmithKline. Anke-Hilse Maitland-van der Zee is funded by a Veni grant from the Netherlands Organization for Scientific Research (NWO). Andrei S Rodin is funded by the grants from PhRMA foundation, NIH, Gilson-Longenbaugh foundation and UTHSC Office of Biotechnology Seed Grant Program. He holds (minor) stock in Pfizer. Jan AM Raaijmakers is a part-time professor at the Utrecht University and vice president external scientific collaborations for GlaxoSmithKline in Europe and holds stock in GlaxoSmithKline. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.